Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre

References

• Deng ZJ, Li L, Teng YX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Transl Hepatol. 2022;10(1):147–158. doi:10.14218/JCTH.2021.00179
   PubMed Web of Science ®Google Scholar
• Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22(32):7289–7300. doi:10.3748/wjg.v22.i32.7289
   PubMed Web of Science ®Google Scholar
• Xiang X, Lau WY, Wu ZY, et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. Eur J Surg Oncol. 2019;45(8):1460–1467. doi:10.1016/j.ejso.2019.03.042
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871–873. doi:10.1093/annonc/mdy510
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Korean Liver Cancer Association; National Cancer Center. 2018 Korean Liver cancer association-national cancer center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13(3):227–299. doi:10.5009/gnl19024
   PubMed Web of Science ®Google Scholar
• Shao YY, Wang SY, Lin SM. Diagnosis Systemic Therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan liver cancer association and the gastroenterological society of Taiwan. J Formos Med Assoc. 2021;120(4):1051–1060. doi:10.1016/j.jfma.2020.10.031
   PubMed Web of Science ®Google Scholar
• Jiang JF, Lao YC, Yuan BH, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget. 2017;8(20):33911–33921. doi:10.1038/s41575-020-00395-0
   PubMedGoogle Scholar
• Josep ML, Thierry DB, Laura K, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Francesco T, Giulia N, Francesca B, Chiara F, Elisabetta G, Alessandro G. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol. 2018;5(1):HEP01. doi:10.2217/hep-2017-0020
   PubMed Web of Science ®Google Scholar
• Yin J, Bo WT, Sun J, et al. New evidence and perspectives on the management of hepatocellular carcinoma with portal vein tumor thrombus. J Clin Transl Hepatol. 2017;5(2):169–176. doi:10.14218/JCTH.2016.00071
   PubMedGoogle Scholar
• Wei XB, Jiang YB, Zhang XP, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141–2151. doi:10.1200/JCO.18.02184
   PubMed Web of Science ®Google Scholar
• Yu JI, Lee SJ, Lee JY, et al. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med. 2019;8(6):6986–6994. doi:10.1002/cam4.2570
   PubMedGoogle Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver cancer study group of Japan. survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016:65 (5):938–943. doi:10.1016/j.jhep.2016.05.044
   Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Sangro B, Park J-W, Cruz CMD, et al. A randomized, multicenter, Phase 3 study of nivolumab vs sorafenib as first line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): checkMate-459. J Clin Oncol. 2016;34(15_suppl):TPS4147–TPS4147. doi:10.1200/JCO.2016.34.15_suppl.TPS4147
   Google Scholar
• Cheng A-L, Qin S, Ikeda M, et al. LBA3IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol. 2019;30(Supplement9):ix183–202. doi:10.1093/annonc/mdz446.002
   Google Scholar
• Yau T, Kang Y-K, Kim T-Y, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol. 2019;37(15_suppl):4012. doi:10.1200/JCO.2019.37.15_suppl.4012
   Web of Science ®Google Scholar
• Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210–219. doi:10.1016/j.intimp.2017.03.015
   PubMed Web of Science ®Google Scholar
• Flynn MJ, Larkin JMG. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert Opin Pharmacother. 2017;18(14):1477–1490. doi:10.1080/14656566.2017.1369956
   PubMed Web of Science ®Google Scholar
• Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for Hepatocellular Carcinoma: new Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108(9):djw133. doi:10.1093/jnci/djw133
   PubMedGoogle Scholar
• Kamiyama T, Nakanishi K, Yokoo H, et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Int J Clin Oncol. 2007;12(5):363–368. doi:10.1007/s10147-007-0701-y
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol off J Am Soc Clin Oncol. 2016;34(5):452–459. doi:10.1200/JCO.2015.61.4925
   PubMed Web of Science ®Google Scholar
• Kang J-K, Kim M-S, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424–5431. doi:10.1002/cncr.27533
   PubMed Web of Science ®Google Scholar
• Bujold A, Massey CA, Kim JJ, et al. Sequential Phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639. doi:10.1200/JCO.2012.44.1659
   PubMed Web of Science ®Google Scholar
• ArnoldKM F, RabenA RL, YuY DAP, et al. The Impact of Radiation on the Tumor Microenvironment: effect of Dose and Fractionation Schedules. Cancer Growth Metastasis. 2018;11:1179064418761639. doi:10.1177/1179064418761639
   Web of Science ®Google Scholar
• Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503–510. doi:10.1016/j.ctrv.2015.03.011
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059. doi:10.1038/nm1622
   PubMed Web of Science ®Google Scholar
• Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond. Front Immunol. 2020;11(1):1–13. doi:10.3389/fimmu.2020.568759
   PubMedGoogle Scholar
• Ohm JE, Gabrilovich DII, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878–4886. doi:10.1182/blood-2002-07-1956
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615. doi:10.1038/nm.3541
   PubMed Web of Science ®Google Scholar
• Ma L, Hernandez MO, Zhao Y, et al. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell. 2019;36(4):418–430.e6. doi:10.1016/j.ccell.2019.08.007
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Merle P, et al. Primary Results from the Phase 3 LEAP-002 Study: lenvatinib Plus Pembrolizumab Versus Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma. Ann Oncol. 2022;33:S1401.
   Web of Science ®Google Scholar